Your browser doesn't support javascript.
loading
Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance.
Wang, Li-Min; Wang, Pingyuan; Chen, Xiao-Min; Yang, Hui; Song, Shan-Shan; Song, Zilan; Jia, Li; Chen, Hua-Dong; Bao, Xu-Bin; Guo, Ne; Huan, Xia-Juan; Xi, Yong; Shen, Yan-Yan; Yang, Xin-Ying; Su, Yi; Sun, Yi-Ming; Gao, Ying-Lei; Chen, Yi; Ding, Jian; Lang, Jing-Yu; Miao, Ze-Hong; Zhang, Ao; He, Jin-Xue.
Afiliação
  • Wang LM; State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Wang P; University of Chinese Academy of Sciences, Beijing, China.
  • Chen XM; State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Yang H; Pharm-X Center, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
  • Song SS; Institute of Evolution and Marine Biodiversity, Ocean University of China, Qingdao, China.
  • Song Z; University of Chinese Academy of Sciences, Beijing, China.
  • Jia L; The CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.
  • Chen HD; State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Bao XB; University of Chinese Academy of Sciences, Beijing, China.
  • Guo N; State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Huan XJ; University of Chinese Academy of Sciences, Beijing, China.
  • Xi Y; Pharm-X Center, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
  • Shen YY; State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Yang XY; University of Chinese Academy of Sciences, Beijing, China.
  • Su Y; State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Sun YM; University of Chinese Academy of Sciences, Beijing, China.
  • Gao YL; State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Chen Y; University of Chinese Academy of Sciences, Beijing, China.
  • Ding J; State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Lang JY; University of Chinese Academy of Sciences, Beijing, China.
  • Miao ZH; State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Zhang A; University of Chinese Academy of Sciences, Beijing, China.
  • He JX; State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
EMBO Mol Med ; 15(3): e16235, 2023 03 08.
Article em En | MEDLINE | ID: mdl-36652375
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interferon Tipo I / Neoplasias Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interferon Tipo I / Neoplasias Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article